Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksABAL.L Regulatory News (ABAL)

  • There is currently no data for ABAL

Trading Update

25 Oct 2012 07:00

RNS Number : 4783P
Imaginatik PLC
25 October 2012
Β 

ο»Ώ

25 October 2012

Imaginatik Plc

("Imaginatik" or the "Company")

Β 

Trading Update

Β 

Imaginatik plc (AIM: IMTK.L), the world's first full service innovation provider offeringΒ a range of technology products and consultancy, is pleased to provide a trading update for the six months ended 30 September 2012.

Β 

As announced at the time of the AGM on 14 September, Imaginatik made good progress in the first half of the financial year. As anticipated at the AGM, the Company successfully contracted a further five additional customers in the last few weeks of the period, bringing the total number of new customers in the first half to 17 (H1 2011: 6). Of these, nine were annual contracts (including Air Products and Chemicals Inc. and Chartis Global Services, Inc.), five were pilot projects (including MillerCoors and Merck & Co. Inc.) with the balance being consultancy-led engagements.

Β 

Revenue for the first half is expected to be approximately Β£1.75m, (H1 2011: Β£1.62m) with operating losses, before share-based payments, expected to be approximately Β£0.36m (H1 2011: Β£0.43m). During the period the Company has capitalised development costs amounting to Β£0.12m, (H1 2011: Β£nil).

Β 

One of the annual contracts referred to above was the conversion of a consultancy-led engagement with a major international US based mining company. The company had been a consultancy customer of Imaginatik's since January 2012. This conversion further reinforces Imaginatik's strategy to offer a 'full service' innovation platform combining software with a mixture of strategic and operational consultancy.

Β 

The Company expects to announce its interim results for the six months ended 30 September 2012 towards the end of November.

Β 

Matt Cooper, Executive Chairman of Imaginatik, commented: "We are pleased to see further evidence that our transition to a full service innovation provider is starting to bear fruit, in particular our consulting capabilities continue to differentiate us from our competitors. Trading in the second half has begun well and, with a strong pipeline of opportunities and renewals for the second half, we remain confident of a successful outcome for the year as a whole."

Β 

Β 

For further information please contact:

Β 

Imaginatik plc

Tel: 020 7917 2975

Matt Cooper, Executive Chairman / Shawn Taylor, CFO

Northland Capital Partners Limited

Tel: 020 7796 8800

Gavin Burnell / Edward Hutton

Newgate Threadneedle

Tel: 020 7653 9850

Caroline Evans-Jones / Hilary Millar

Β 

About Imaginatik

Β 

Imaginatik provides a range of Innovation solutions comprised of consultancy, enterprise software and program management to deliver innovation results to companies such as The World Bank, The Chubb Group of Insurance Companies, Boeing, Pfizer, Goodyear, Paccar, Kellogg and Cargill. Few companies possess the internal capability to consistently generate fresh ideas, identify those worth pursuing and reliably transform them into real, value-enhancing assets. Imaginatik's mission is to help these companies build sustainable innovation competencies.

Imaginatik is a public company whose shares are traded on the AIM market of the London Stock Exchange (LSE:IMTK.L) and is a World Economic Forum Technology Pioneer with offices in Boston, MA, and Winchester, UK. For more information visitΒ www.imaginatik.com.

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
TSTPGGUUUUPPGMC
Date   Source Headline
28th Jul 20154:07 pmRNSHolding(s) in Company
24th Jul 201512:50 pmRNSHolding(s) in Company
21st Jul 20155:31 pmRNSHolding(s) in Company
20th Jul 20157:00 amRNSSubscription and Director Dealings
15th Jul 20157:00 amRNSFinal Results
10th Jul 20159:23 amRNSHolding(s) in Company
1st Jul 20157:00 amRNSContract Win
29th Jun 20155:11 pmRNSHolding(s) in Company
29th Jun 20155:10 pmRNSHolding(s) in Company
29th Jun 201510:30 amRNSHolding(s) in Company
25th Jun 20157:00 amRNSHolding(s) in Company
25th Jun 20157:00 amRNSHolding(s) in Company
23rd Jun 20155:15 pmRNSHolding(s) in Company
23rd Jun 20157:00 amRNSHolding(s) in Company
22nd Jun 20157:00 amRNSMarket Update
1st Jun 20152:38 pmRNSResult of General Meeting
15th May 20157:00 amRNSPosting of Circular
14th May 20157:00 amRNSProposed Issue of Equity
13th Apr 20157:00 amRNSContract Wins
30th Mar 20157:00 amRNSContract Extension
16th Feb 20157:00 amRNSContracts win
11th Feb 20158:05 amRNSTrading Update
19th Jan 20157:00 amRNSDirector Loan
22nd Dec 201410:30 amRNSGrant of Options
17th Dec 20147:00 amRNSFive Year Contract Win
16th Dec 20147:00 amRNSContract Win
8th Dec 20147:00 amRNSInterim Results
19th Nov 20147:00 amRNSDirectorate Change
14th Nov 201411:52 amRNSBlocklisting Interim Review
24th Oct 20147:00 amRNSIssue of Equity/Director's Dealing
7th Oct 20145:04 pmRNSDirector/PDMR Shareholding
27th Aug 201410:50 amRNSHolding(s) in Company
21st Aug 20141:31 pmRNSDirector/PDMR Shareholding
18th Aug 20141:37 pmRNSHolding(s) in Company
14th Aug 20141:38 pmRNSResult of AGM
22nd Jul 20147:00 amRNSProposed Share Consolidation and Notice of AGM
1st Jul 20147:00 amRNSFinal Results
16th May 201411:40 amRNSHolding(s) in Company
15th May 20148:50 amRNSBlocklisting Interim Review
13th May 201411:47 amRNSHolding(s) in Company
12th May 20144:14 pmRNSResult of General Meeting and Exercise of Options
25th Apr 20147:00 amRNSProposed Placing and Subscription
14th Apr 20147:00 amRNSContract Wins and Trading Update
18th Mar 20147:00 amRNSContract Wins
28th Feb 201410:35 amRNSDirector's Dealing
26th Feb 201412:39 pmRNSDirector's Dealing
19th Dec 20133:38 pmRNSHolding(s) in Company
18th Dec 20137:00 amRNSExercise and Grant of Options
13th Dec 20137:00 amRNSContract Extension
3rd Dec 20137:00 amRNSBlocklisting Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.